ROCHESTER GENERAL HOSPITAL
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1847-01-01
- Employees
- -
- Market Cap
- -
Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05764993
- Locations
- 🇺🇸
Rochester Regional Health Ctr for Clinical Research - Alexander Park, Rochester, New York, United States
🇺🇸Rochester Regional Health - Ctr for Clinical Research - Linden Oaks, Rochester, New York, United States
🇺🇸Rochester Regional Health - Ctr for Clinical Research - Greece, Rochester, New York, United States
Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 320
- Registration Number
- NCT04946084
- Locations
- 🇺🇸
Rochester General Hospital, Rochester, New York, United States
Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03730129
- Locations
- 🇺🇸
Allergy, Immunology, Rheumatology at Rochester Regional Health, Rochester, New York, United States
Dupilumab for Aspirin-exacerbated Respiratory Disease
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT03595488
- Locations
- 🇺🇸
Rochester Regional Health - Allergy/Immunology, Rochester, New York, United States
Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig
- Conditions
- Interventions
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT03211065
- Locations
- 🇺🇸
Allergy and Immunology, 222 Alexander Street, Rochester, New York, United States
Oral Vancomycin for Preventing Clostridium Difficile Recurrence
- Conditions
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT03200093
- Locations
- 🇺🇸
Rochester General Hospital, Rochester, New York, United States
Evaluate Pathogens and Immunity to Acute Otitis Media in Healthy Children.
- Conditions
- Interventions
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 1320
- Registration Number
- NCT02591563
- Locations
- 🇺🇸
Rochester General Hospital, Rochester, New York, United States
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 1
- Registration Number
- NCT02341209
- Locations
- 🇺🇸
Rochester General Hospital, Rochester, New York, United States
Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Rochester General Hospital
- Registration Number
- NCT02301494
Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Rochester General Hospital
- Registration Number
- NCT02118688
- Locations
- 🇺🇸
Rochester General Hospital, Rochester, New York, United States